Stockreport

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Jelmyto® granted expedited review in IsraelJelmyto is the only US FDA approved treatment for low-grade upper tract urothelial cancer PRINCETON, N.J.--(BUSINESS WIRE)- [Read more]